Preliminary Results of Phase III clinical study of KUC-7483

Kissei Pharmaceutical Co., Ltd. (President and CEO: Mutsuo Kanzawa) announced that preliminary analysis on Phase III clinical study of KUC-7483 (a treatment for overactive bladder) indicated that the study's primary efficacy endpoint was not met.

Kissei Pharmaceutical Co., Ltd. will perform a detailed analysis of this study and make a decision regarding the possibility for further clinical development of KUC-7483.

<Reference>
Overactive bladder:
Overactive bladder is associated with symptoms, such as, urinary frequency, urgency and urge incontinence